A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Pruritus
  • Focus Registrational; Therapeutic Use
  • Sponsors Trevi Therapeutics
  • Most Recent Events

    • 16 Nov 2016 According to a Trevi Therapeutics media release, data from the study will be presented during an oral abstract presentation at the American Society of Nephrology's Kidney Week 2016.
    • 01 Mar 2016 According to the Trevi Therapeutics media release, data from this trial will be presented at the American Academy of Dermatologys 74th Annual Meeting
    • 22 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top